Archive for May, 2004

The Drug Research War

The Drug Research War “Mention the term ‘outsourcing,’ and drug development probably doesn’t leap to mind. But this market, which is the heart of pharmaceutical and biotech companies, is growing at a yearly clip of 15% to 20%. Right now the lion’s share of the work has gone to U.S. companies that focus on drug […]


Click here for reuse options!
Copyright 2004 Biotechblog

Biotechs struggle as IPOs find cool reception

Biotechs struggle as IPOs find cool reception “Five initial public offerings had trading debuts Thursday, bringing mixed results and a message that biotech certainly isn’t what the doctor ordered for the IPO market. “


Click here for reuse options!
Copyright 2004 Biotechblog

The Health-Care Catastrophe That Won’t Happen

The Health-Care Catastrophe That Won’t Happen Why biotech gains will rein in medical costs. The lesson of info tech


Click here for reuse options!
Copyright 2004 Biotechblog

Will U.S. try to circumvent drug firms patent?

Will U.S. try to circumvent drug firms patent? : The furor over Abbott Laboratories’ 400 percent price increase last December of the AIDS drug Norvir has resulted in an unprecedented meeting at the National Institutes of Health to consider circumventing the drug giant’s patent.


Click here for reuse options!
Copyright 2004 Biotechblog

Another gene genie out of the bottle

Another gene genie out of the bottle The European Commission has lifted a five-year moratorium on genetically modified produce, by allowing the sale in Europe of one type of modified corn. But the battle by producers of such crops to win governments� and consumers� acceptance is far from over


Click here for reuse options!
Copyright 2004 Biotechblog

Could patients glean stock tips?: Drug trial participants may be insider trading.

Could patients glean stock tips?: Drug trial participants may be insider trading. “Patients in clinical trials might be using information about the drug they are taking to trade illegally in pharmaceutical stocks, warns a group of doctors and bioethicists. But they have no idea how prevalent the problem might be.”


Click here for reuse options!
Copyright 2004 Biotechblog

Financial Snapshot For March 2004: Looking Good

Financial Snapshot For March 2004: Looking Good “It’s been a rocky first quarter for the biotech stocks � and for the markets in general. Yet, despite investors’ nervousness � about issues as diverse as the terrorist train bombing in Madrid and the departure of Mark McClellan from the FDA � the biotech sector managed to […]


Click here for reuse options!
Copyright 2004 Biotechblog

%d bloggers like this: